Quantcast

Latest Catecholamines Stories

2014-10-29 16:28:45

REHOVOT, Israel, October 29, 2014 /PRNewswire/ -- Company also reports encouraging partial results from Phase IIa study of continuous, subcutaneously delivered high-dose liquid levodopa/carbidopa (ND0612H) therapy for advanced patients Data presented at the Michael J. Fox Foundation 2014 Parkinson's Disease Therapeutics Conference NeuroDerm Ltd., a clinical-stage pharmaceutical...

2014-10-27 08:29:21

Survey Findings Reveal Incidence of First-Time Reactions in School Setting PITTSBURGH, Oct. 27, 2014 /PRNewswire/ -- Mylan Specialty, the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced new EpiPen4Schools(®) program offerings as part of the company's commitment to support the growing need for education among school staff about anaphylaxis, a life-threatening allergic reaction. The EpiPen4Schools program, launched in 2012, provides four free...

2014-10-23 08:34:33

REHOVOT, Israel, October 23, 2014 /PRNewswire/ -- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that top-line results for ND0612L from a phase II study in patients with moderate Parkinson's patients, and preliminary interim results from a phase IIA study of ND0612H and ND0612L in advanced Parkinson's patients, will be presented at The Michael J. Fox Foundation's 2014 Parkinson's Disease...

breakfast
2014-10-18 05:55:56

Brett Smith for redOrbit.com - Your Universe Online Nutritionists have long-advocated for starting the day with a complete breakfast and now a new study from the University of Missouri has found that a breakfast particularly high in protein can lower cravings for unhealthy foods later in the day. Published in the Nutrition Journal, the new study concluded that young adults eating a breakfast high in protein showed increased levels of a brain chemical associated with feelings of reward...

2014-10-14 12:26:46

Sales of a Novel Antipsychotic and an Improved Rescue Therapy Will Contribute Approximately $1 Billion to the PD Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that the Parkinson's disease (PD) pharmacotherapy market will grow 5 percent annually from $2.3 billion in 2013 to $3.8 billion in 2023. This growth will be fueled by the launch of several emerging therapies--including new molecular...

2014-09-03 12:30:29

Continuous levodopa therapy with ND0612H has the potential to prevent or delay the need for surgical intervention in patients with severe stage Parkinson's disease REHOVOT, Israel, September 3, 2014 /PRNewswire/ -- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first patients with severe Parkinson's disease have been enrolled and dosed in a Phase IIa trial of ND0612H. ND0612H is a...

2014-08-21 16:24:23

REHOVOT, Israel, August 21, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. The company plans to use the funding to further the clinical and regulatory...

2014-08-04 08:27:58

REHOVOT, Israel, August 4, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). According to EMA guidelines, the EMA can allow products for which the centralized...

2014-07-24 11:40:21

UCI News Flawed dopamine signaling linked to mass alteration of gene activity in prefrontal cortex Dysfunction in dopamine signaling profoundly changes the activity level of about 2,000 genes in the brain’s prefrontal cortex and may be an underlying cause of certain complex neuropsychiatric disorders, such as schizophrenia, according to UC Irvine scientists. This epigenetic alteration of gene activity in brain cells that receive this neurotransmitter showed for the first time that...

Parkinson's Enhances Creativity: Study
2014-07-15 03:26:50

Tel Aviv University New TAU study confirms creative energy in Parkinson's sufferers is greater than in healthy individuals Prof. Rivka Inzelberg of Tel Aviv University's Sackler Faculty of Medicine and the Sagol Neuroscience Center at Sheba Medical Center, Tel Hashomer, documented the exceptional creativity of Parkinson's patients two years ago in a review for Behavioral Neuroscience. Since then, she has conducted the first empirical study to verify a link between Parkinson's disease...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related